TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30865281

Group type: EXPERIMENTAL
Intervention: Asoprisnil 10 mg
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Asoprisnil 25 mg
Number of subjects: 907

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Asoprisnil (both doses)
Number of subjects: 907
Study: 27749412

Group type: EXPERIMENTAL
Intervention: Fluciclovine PET/CT
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 87
Study: 25522302

Group type: EXPERIMENTAL
Intervention: Simple weight control advice plus FTO feedback (FA)
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Higher-risk genetic results
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Lower-risk genetic results
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Weight control advice alone (AO)
Number of subjects: 1016
Study: 23478473

Group type: EXPERIMENTAL
Intervention: 20-week specific strength training for the neck/shoulders
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 20-week specific strength training for the neck/shoulders (per protocol adherence)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 20-week specific strength training for the neck/shoulders (medium adherence)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 20-week specific strength training for the neck/shoulders (high adherence)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study: 22619908

Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspiration (MVA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sharp Curettage
Number of subjects: 48
Study: 19746769

Group type: EXPERIMENTAL
Intervention: Adapalene-BPO combination gel
Number of subjects: 1668

Group type: COMPARATOR
Intervention: Adapalene monotherapy
Number of subjects: 1668

Group type: COMPARATOR
Intervention: BPO monotherapy
Number of subjects: 1668

Group type: COMPARATOR
Intervention: Gel vehicle
Number of subjects: 1668
Study: 17990463

Group type: EXPERIMENTAL
Intervention: Xiaoshui Powder
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (conventional treatment only)
Number of subjects: 60
Study: 15053839

Group type: EXPERIMENTAL
Intervention: Active role in decision-making
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Collaborative role in decision-making
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Passive role in decision-making
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Family involvement in decision-making (cancer vignette)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Respecting physician's opinion
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Family's preference importance
Number of subjects: 134
Study: 11401053

Group type: EXPERIMENTAL
Intervention: Histamine (HIST)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Methacholine (MTH)
Number of subjects: 11
Study: 9553291

Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine combined with standard measles-mumps-rubella vaccine
Number of subjects: 118
Study: 8635378

Group type: EXPERIMENTAL
Intervention: Participants informed of the NC's monitoring function
Number of subjects: 231

Group type: COMPARATOR
Intervention: Participants not informed of the NC's monitoring function
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Overall compliance trends
Number of subjects: 231
Study: 2404633

Group type: EXPERIMENTAL
Intervention: Supervised treadmill walking (1 hr/day, 3 days/wk, for 12 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 19
Study: 7378989

Group type: EXPERIMENTAL
Intervention: Melphalan (MEL) 0.2 mg/kg/day for five days every four weeks
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Melphalan (MEL) plus 5-fluorouracil (FU) 15 mg/kg/day for five days every four weeks
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Melphalan (MEL) plus 5-fluorouracil (FU) and dactinomycin (AC) 0.5 mg daily for five days every four weeks
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Cytoxan (CY) 7 mg/kg/day, FU 8 mg/kg/day and AC 0.5 mg/day for five days every four weeks
Number of subjects: 427
Study: 30893159

Group type: EXPERIMENTAL
Intervention: 1.5-mL reconstitution of abobotulinumtoxinA (50 units)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.5-mL reconstitution of abobotulinumtoxinA (50 units)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both reconstitutions
Number of subjects: 60
Study: 28078503

Group type: EXPERIMENTAL
Intervention: HILT + GCS + EX
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: GCS + EX
Number of subjects: 67

Group type: COMPARATOR
Intervention: PL + EX
Number of subjects: 67
Study: 24425525

Group type: EXPERIMENTAL
Intervention: Spin exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study: 23531557

Group type: EXPERIMENTAL
Intervention: Bismuth shielding during endovascular coil embolisation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unshielded group during endovascular coil embolisation
Number of subjects: 60
Study: 20873907

Group type: EXPERIMENTAL
Intervention: Stepped care (N = 84)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Care as usual (N = 85)
Number of subjects: 171
Study: 19011503

Group type: EXPERIMENTAL
Intervention: Nebulized arformoterol 15 microg BID
Number of subjects: 1429

Group type: EXPERIMENTAL
Intervention: Nebulized arformoterol 25 microg BID
Number of subjects: 1429

Group type: EXPERIMENTAL
Intervention: Nebulized arformoterol 50 microg QD
Number of subjects: 1429

Group type: EXPERIMENTAL
Intervention: Salmeterol metered dose inhaler 42 microg BID
Number of subjects: 1429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1429
Study: 16799816

Group type: EXPERIMENTAL
Intervention: High carbohydrate intake (HC) - 9.3 +/- 0 g CHO kg(‐1) day(‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low carbohydrate intake (LC) - 0.6 +/- 0.1 g CHO kg(‐1) day(‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low carbohydrate intake (LC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High carbohydrate intake (HC)
Number of subjects: 8
Study: 14719987

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative chemoradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation doses ≥40 grays (Gy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative irradiation
Number of subjects: 0
Study: 11056095

Group type: EXPERIMENTAL
Intervention: Patients with periodic breathing (PB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Patients without periodic breathing (PB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy normal subjects
Number of subjects: 30
Study: 8712118

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg plus diltiazem ER 60 mg
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg plus diltiazem ER 120 mg
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg plus diltiazem ER 180 mg
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg plus diltiazem ER 240 mg
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg alone
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 1827000

Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 or 5 mg twice daily)
Number of subjects: 883

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5 mg or 25 mg twice daily)
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Open-label enalapril (2.5 to 10 mg twice daily)
Number of subjects: 883
Study: 6129870

Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 312
Study: 30640287

Group type: EXPERIMENTAL
Intervention: Functional Resistance Training (FRT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Traditional Resistance Training (TRT)
Number of subjects: 34
Study: 28378764

Group type: EXPERIMENTAL
Intervention: Brief stage‐matched smoking cessation intervention (20‐minute individualized face‐to‐face counseling by trained nurses and a diabetes mellitus‐specific leaflet)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Brief stage‐matched smoking cessation intervention
Number of subjects: 557
Study: 24947112

Group type: EXPERIMENTAL
Intervention: Contralateral risk-reducing mastectomy (CRRM); 242 patients (42%) underwent CRRM.
Number of subjects: 583

Group type: COMPARATOR
Intervention: Surveillance; 341 patients (58%) remained under surveillance.
Number of subjects: 583
Study: 24459240

Group type: EXPERIMENTAL
Intervention: Regulation of Cues (ROC) program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 22710369

Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 21
Study: 19998578

Group type: EXPERIMENTAL
Intervention: Otalgan ear drops containing procaine hydrochloride and phenazone
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Otalgan ear drops
Number of subjects: 428
Study: 17303622

Group type: EXPERIMENTAL
Intervention: Diamorphine 70 microg ml(‐1) and levobupivacaine (testing interval 0.004%w/v, starting at 0.044%w/v)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.044%w/v (fixed) and diamorphine (testing interval 7 microg ml(‐1), starting at 70 microg ml(‐1))
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fixed combination of diamorphine 69.5 microg ml(‐1) (60.5‐78.5) and levobupivacaine 0.044%w/v (0.039‐0.049)
Number of subjects: 120
Study: 15449747

Group type: EXPERIMENTAL
Intervention: Continuous infusion of low dose morphine with bupivacaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Group II (not specified intervention)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Group III (not specified intervention)
Number of subjects: 48
Study: 11394734

Group type: EXPERIMENTAL
Intervention: Lansoprazole-based triple therapy (LAN 30 mg BID, clarithromycin 500 mg BID, tinidazole 500 mg BID for 1 week, followed by LAN 30 mg BID for 3 weeks)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Ranitidine bismuth citrate-based dual therapy (RBC 400 mg BID plus clarithromycin 500 mg BID for 2 weeks, followed by RBC 400 mg BID for 2 weeks)
Number of subjects: 185
Study: 9715777

Group type: EXPERIMENTAL
Intervention: Health professionals locating the carotid pulse in less than 5 s
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Health professionals locating the carotid pulse in less than 10 s
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Influence of CPR training on pulse detection
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Neck position during pulse detection
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Overall performance of health professionals
Number of subjects: 72
Study: 7992431

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection into the abdominal wall (SCA)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intramuscular injection into the thigh (IMT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Subcutaneous injection into the thigh (SCT)
Number of subjects: 49
Study: 2965461

Group type: EXPERIMENTAL
Intervention: anti‐human HBs immunoglobulin (HB Ig) and HB vaccine
Number of subjects: 29
Study: 31175908

Group type: EXPERIMENTAL
Intervention: Online care
Number of subjects: 296

Group type: COMPARATOR
Intervention: In-person care
Number of subjects: 296
Study: 30358937

Group type: EXPERIMENTAL
Intervention: Minimal maxillary ostial dilation via balloon sinuplasty
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mega‐antrostomy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mini‐antrostomy
Number of subjects: 12
Study: 27227651

Group type: EXPERIMENTAL
Intervention: ConfID (Internet intervention)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 179
Study: 26223493

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study: 23247552

Group type: EXPERIMENTAL
Intervention: Sharp scalpel debridement of painful forefoot plantar callosities in conjunction with a combined therapeutic approach
Number of subjects: 65

Group type: COMPARATOR
Intervention: Combined therapeutic approach alone
Number of subjects: 65
Study: 21251031

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18834319

Group type: EXPERIMENTAL
Intervention: 48 weeks of pegylated interferon-alpha-2a (180 microg per week) plus ribavirin (1000-1200 mg/day) therapy
Number of subjects: 308

Group type: COMPARATOR
Intervention: 24 weeks of pegylated interferon-alpha-2a (180 microg per week) plus ribavirin (1000-1200 mg/day) therapy
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: 48 weeks of therapy
Number of subjects: 308

Group type: COMPARATOR
Intervention: 24 weeks of therapy
Number of subjects: 308
Study: 16488138

Group type: EXPERIMENTAL
Intervention: Lidocaine/epinephrine/fentanyl mixture
Number of subjects: 68

Group type: COMPARATOR
Intervention: Plain 0.5% bupivacaine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study: 13680547

Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 10676668

Group type: EXPERIMENTAL
Intervention: Marine omega-3 fatty acids (4 g/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9175408

Group type: EXPERIMENTAL
Intervention: School-based intervention
Number of subjects: 1364

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1364
Study: 8380185

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3953429

Group type: EXPERIMENTAL
Intervention: Regular verapamil (80 to 120 mg, 3 times a day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sustained-release verapamil (240 to 360 mg once a day)
Number of subjects: 22
Study: 29661592

Group type: EXPERIMENTAL
Intervention: bipolar TURB (bTURB)
Number of subjects: 716
Study: 27920513

Group type: EXPERIMENTAL
Intervention: Discair® inhalation (18 μg once-daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: HandiHaler® inhalation (18 μg once-daily)
Number of subjects: 58
Study: 25015763

Group type: EXPERIMENTAL
Intervention: 0.25 mg repaglinide, oral, twice daily (group A)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 0.25 mg repaglinide, oral, three times daily (group B)
Number of subjects: 43
Study: 22618094

Group type: EXPERIMENTAL
Intervention: Assist/control plus volume guarantee (VG) ventilation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Assist/control (A/C)
Number of subjects: 45
Study: 21302687

Group type: EXPERIMENTAL
Intervention: Lidocaine spray 10%
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tetracaine 2% solution
Number of subjects: 48
Study: 17269956

Group type: EXPERIMENTAL
Intervention: 12 group‐discussion sessions with self‐directed learning
Number of subjects: 77

Group type: COMPARATOR
Intervention: 12 formal lectures
Number of subjects: 77
Study: 15481062

Group type: EXPERIMENTAL
Intervention: Oral 6MP plus prednisone (OP)
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Intravenous 6MP plus prednisone (IP)
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Oral 6MP plus dexamethasone (OD)
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Intravenous 6MP plus dexamethasone (ID)
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Oral 6MP during consolidation
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Intravenous 6MP during consolidation
Number of subjects: 1060
Study: 12043766

Group type: EXPERIMENTAL
Intervention: No tourniquet
Number of subjects: 34

Group type: COMPARATOR
Intervention: Tourniquet
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 10210339

Group type: COMPARATOR
Intervention: 4 litres of PEG-saline solution and 15 mg of bisacodyl (SELG-4)
Number of subjects: 348

Group type: COMPARATOR
Intervention: 156 mg of sennosides, 15 g of magnesium sulphate, and 2 litres of water (SennMg)
Number of subjects: 348

Group type: COMPARATOR
Intervention: 156 mg of sennosides and 2 litres of PEG-saline solution (SennSELG)
Number of subjects: 348
Study: 7887640

Group type: EXPERIMENTAL
Intervention: 3.75 mg TAP-144-SR
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 7.5 mg TAP-144-SR
Number of subjects: 106
Study: 2240542

Group type: EXPERIMENTAL
Intervention: Lignocaine‐prilocaine cream applied for 5 minutes
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lignocaine‐prilocaine cream applied for 60 minutes
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 120

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 120
Study: 1120946

Group type: EXPERIMENTAL
Intervention: Success treatment for underachievers
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Failure treatment for overachievers
Number of subjects: 22
Study: 31298712

Group type: EXPERIMENTAL
Intervention: Medicaid insurance type
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Private insurance type
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Clinics with more than 3 practitioners
Number of subjects: 194

Group type: COMPARATOR
Intervention: Clinics with single practitioners
Number of subjects: 194

Group type: COMPARATOR
Intervention: Insurance status (Medicaid vs Private)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Clinics offering medications for opioid use disorders
Number of subjects: 194
Study: 28668575

Group type: EXPERIMENTAL
Intervention: MenC‐TT vaccine
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: MenACWY‐TT vaccine
Number of subjects: 501
Study: 26714417

Group type: EXPERIMENTAL
Intervention: Paternal lymphocytes combined with vitamin D3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paternal lymphocytes alone (Control)
Number of subjects: 0
Study: 23759085

Group type: EXPERIMENTAL
Intervention: Bipolar endometrial ablation
Number of subjects: 126

Group type: COMPARATOR
Intervention: Balloon ablation
Number of subjects: 126
Study: 21631695

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg once daily
Number of subjects: 1630

Group type: COMPARATOR
Intervention: Finasteride 5 mg once daily
Number of subjects: 1630
Study: 18828959

Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (EXU)
Number of subjects: 1290
Study: 17007384

Group type: EXPERIMENTAL
Intervention: Radiotherapy with high expressions of CD44H
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Radiotherapy with low expressions of CD44H
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Radiotherapy with high expressions of nm23H1
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Radiotherapy with low expressions of nm23H1
Number of subjects: 62

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 62
Study: 14508195

Group type: EXPERIMENTAL
Intervention: Combination of irbesartan 150 mg and fosinopril 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fosinopril 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Irbesartan 300 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11101060

Group type: EXPERIMENTAL
Intervention: Delavirdine plus adefovir dipivoxil
Number of subjects: 7

Group type: COMPARATOR
Intervention: Delavirdine
Number of subjects: 7
Study: 8829189

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (ceftazidime, amikacine, and metronidazole for 10 days)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Nonantibiotic treatment
Number of subjects: 23
Study: 1463170

Group type: EXPERIMENTAL
Intervention: 6 ml bupivacaine 0.125%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 8 ml bupivacaine 0.125%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 ml bupivacaine 0.125%
Number of subjects: 30
Study: 6422864

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 59

Group type: COMPARATOR
Intervention: Transpyloric feeding
Number of subjects: 59
Study: 30700348

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin sodium combined with magnesium sulfate
Number of subjects: 103

Group type: COMPARATOR
Intervention: Magnesium sulfate (control)
Number of subjects: 103
Study: 29844423

Group type: EXPERIMENTAL
Intervention: Graduated Compression Stockings (GCS) alone (Group A)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: GCS + Low Molecular Weight Heparin (LMWH) (Group B)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: GCS + Intermittent Pneumatic Compression (IPC) (Group C)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: GCS + IPC + LMWH (Group D)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: LMWH-treated patients (Group B + Group D)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Non-LMWH-treated patients (Group A + Group C)
Number of subjects: 625
Study: 27378312

Group type: EXPERIMENTAL
Intervention: Watermelon juice supplementation (300 mL·day−1 for 16 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (apple juice concentrate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Watermelon juice supplementation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study: 25026923

Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-calorie diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Facebook group engagement
Number of subjects: 18
Study: 22192495

Group type: EXPERIMENTAL
Intervention: Iodine-125 ((125)I) brachytherapy
Number of subjects: 259

Group type: COMPARATOR
Intervention: Palladium-103 ((103)Pd) brachytherapy
Number of subjects: 259